SEPTERNA Inc. (US)

Septerna is developing a pipeline of novel small molecule medicines that target GPCRs, providing new drugs or improved alternatives to treat patients with a huge range of diseases (e.g. hypoparathyroidism). Their Native Complex™ Platform can unlock previously untapped GPCRs, addressing the nearly 85% of potential therapeutic GPCR targets that remain undrugged and providing a springboard that could uncover a world of possibilities for new and improved treatments and best-in-class therapies.

Lead Researchers: Patrick Sexton (MIPS) and Arthur Christopoulos (MIPS)
Website: septerna.com